RespireRx Pharmaceuticals Inc. (RSPI)
USD 0.0
(-23.81%)
USD 0.0
(-23.81%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | 2.7 Million USD | 30.35% |
| 2021 | 2.07 Million USD | 23.42% |
| 2020 | 1.68 Million USD | 3.02% |
| 2019 | 1.63 Million USD | 30.75% |
| 2018 | 1.24 Million USD | 8.8% |
| 2017 | 1.14 Million USD | 4.16% |
| 2016 | 1.1 Million USD | 27.77% |
| 2015 | 863.21 Thousand USD | 49.73% |
| 2014 | 576.5 Thousand USD | -3.32% |
| 2013 | 596.3 Thousand USD | 28.13% |
| 2012 | 465.39 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | -100.0% |
| 1999 | 999.28 Thousand USD | 5.38% |
| 1998 | 948.25 Thousand USD | -13.3% |
| 1997 | 1.09 Million USD | 4.43% |
| 1996 | 1.04 Million USD | 4.73% |
| 1995 | 1 Million USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | 0.0% |
| 1992 | - USD | 0.0% |
| 1991 | - USD | 0.0% |
| 1990 | - USD | 0.0% |
| 1989 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q1 | 2.85 Million USD | 5.36% |
| 2023 Q2 | 2.87 Million USD | 0.68% |
| 2023 Q3 | 2.21 Million USD | -22.95% |
| 2022 Q1 | 2.43 Million USD | 17.38% |
| 2022 FY | 2.7 Million USD | 30.35% |
| 2022 Q4 | 2.7 Million USD | 6.0% |
| 2022 Q3 | 2.55 Million USD | 5.6% |
| 2022 Q2 | 2.41 Million USD | -0.79% |
| 2021 FY | 2.07 Million USD | 23.42% |
| 2021 Q4 | 2.07 Million USD | 11.97% |
| 2021 Q1 | 1.55 Million USD | -7.39% |
| 2021 Q3 | 1.85 Million USD | 9.89% |
| 2021 Q2 | 1.68 Million USD | 8.32% |
| 2020 Q1 | 1.49 Million USD | -8.35% |
| 2020 Q3 | 1.64 Million USD | 21.4% |
| 2020 Q4 | 1.68 Million USD | 2.34% |
| 2020 FY | 1.68 Million USD | 3.02% |
| 2020 Q2 | 1.35 Million USD | -9.52% |
| 2019 FY | 1.63 Million USD | 30.75% |
| 2019 Q3 | 1.52 Million USD | 0.85% |
| 2019 Q1 | 1.43 Million USD | 14.5% |
| 2019 Q2 | 1.51 Million USD | 5.77% |
| 2019 Q4 | 1.63 Million USD | 7.05% |
| 2018 Q2 | 1.24 Million USD | -7.0% |
| 2018 Q1 | 1.33 Million USD | 16.13% |
| 2018 Q4 | 1.24 Million USD | 4.8% |
| 2018 Q3 | 1.19 Million USD | -3.88% |
| 2018 FY | 1.24 Million USD | 8.8% |
| 2017 Q4 | 1.14 Million USD | -6.92% |
| 2017 FY | 1.14 Million USD | 4.16% |
| 2017 Q3 | 1.23 Million USD | 0.35% |
| 2017 Q2 | 1.22 Million USD | 1.88% |
| 2017 Q1 | 1.2 Million USD | 9.45% |
| 2016 Q1 | 1.13 Million USD | 31.17% |
| 2016 Q4 | 1.1 Million USD | -14.32% |
| 2016 FY | 1.1 Million USD | 27.77% |
| 2016 Q3 | 1.28 Million USD | 27.59% |
| 2016 Q2 | 1 Million USD | -10.9% |
| 2015 Q4 | 863.21 Thousand USD | 10.74% |
| 2015 Q2 | 1.02 Million USD | 34.12% |
| 2015 Q1 | 762.92 Thousand USD | 32.34% |
| 2015 FY | 863.21 Thousand USD | 49.73% |
| 2015 Q3 | 779.48 Thousand USD | -23.82% |
| 2014 Q4 | 576.5 Thousand USD | 7.78% |
| 2014 FY | 576.5 Thousand USD | -3.32% |
| 2014 Q1 | 526.97 Thousand USD | -11.63% |
| 2014 Q3 | 534.86 Thousand USD | -6.07% |
| 2014 Q2 | 569.43 Thousand USD | 8.06% |
| 2013 Q4 | 596.3 Thousand USD | 10.78% |
| 2013 Q2 | 813.54 Thousand USD | 78.21% |
| 2013 Q1 | 456.51 Thousand USD | -1.91% |
| 2013 FY | 596.3 Thousand USD | 28.13% |
| 2013 Q3 | 538.29 Thousand USD | -33.83% |
| 2012 Q4 | 465.39 Thousand USD | 28.58% |
| 2012 Q3 | 361.94 Thousand USD | 33.07% |
| 2012 Q2 | 272 Thousand USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 FY | 465.39 Thousand USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | -100.0% |
| 2010 Q1 | 1.33 Million USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | 279.66 Thousand USD | 0.0% |
| 2005 Q2 | - USD | -100.0% |
| 2005 FY | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2000 Q1 | - USD | -100.0% |
| 2000 FY | - USD | -100.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 1999 Q3 | 664.47 Thousand USD | -33.55% |
| 1999 Q1 | 990 Thousand USD | -1.0% |
| 1999 FY | 999.28 Thousand USD | 5.38% |
| 1999 Q4 | 529.05 Thousand USD | -20.38% |
| 1999 Q2 | 1 Million USD | 1.01% |
| 1998 Q1 | 900 Thousand USD | -18.18% |
| 1998 Q4 | 1 Million USD | 0.0% |
| 1998 Q3 | 1 Million USD | 5.46% |
| 1998 FY | 948.25 Thousand USD | -13.3% |
| 1998 Q2 | 948.25 Thousand USD | 5.36% |
| 1997 Q4 | 1.1 Million USD | 0.0% |
| 1997 FY | 1.09 Million USD | 4.43% |
| 1997 Q1 | 1.1 Million USD | 0.0% |
| 1997 Q2 | 1.09 Million USD | -0.57% |
| 1997 Q3 | 1.1 Million USD | 0.57% |
| 1996 Q3 | 1.1 Million USD | 5.03% |
| 1996 Q4 | 1.1 Million USD | 0.0% |
| 1996 Q2 | 1.04 Million USD | 4.73% |
| 1996 Q1 | 1 Million USD | 0.0% |
| 1996 FY | 1.04 Million USD | 4.73% |
| 1995 Q3 | 1 Million USD | 0.0% |
| 1995 Q4 | 1 Million USD | 0.0% |
| 1995 FY | 1 Million USD | 0.0% |
| 1995 Q1 | 20 Thousand USD | 0.0% |
| 1995 Q2 | 1 Million USD | 4900.0% |
| 1994 Q4 | 20 Thousand USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1992 Q2 | - USD | 0.0% |
| 1992 Q3 | - USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1992 Q4 | - USD | 0.0% |
| 1992 Q1 | - USD | 0.0% |
| 1991 Q3 | - USD | 0.0% |
| 1991 Q4 | - USD | 0.0% |
| 1991 FY | - USD | 0.0% |
| 1991 Q1 | - USD | 0.0% |
| 1991 Q2 | - USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 FY | - USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| 1989 Q3 | - USD | 0.0% |
| 1989 Q2 | - USD | 0.0% |
| 1989 Q4 | - USD | 0.0% |
| 1989 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 93.426% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 34.286% |
| SQZ Biotechnologies Company | 27.47 Million USD | 90.14% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 93.755% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 90.9% |
| Mesoblast Limited | 118.7 Million USD | 97.718% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -185.647% |
| Genus plc | 233.1 Million USD | 98.838% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 7.565% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -101.603% |
| Marizyme, Inc. | 18.71 Million USD | 85.528% |
| ContraFect Corporation | 2.88 Million USD | 5.98% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -261.16% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -1899.235% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -87.283% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -16.456% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 52.129% |
| MultiCell Technologies, Inc. | 202.58 USD | -1337002.873% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 95.288% |
| EV Biologics, Inc. | 1.49 Million USD | -81.214% |
| Q BioMed Inc. | 4.1 Million USD | 34.095% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 91.817% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -329.9% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -120.514% |
| Biomind Labs Inc. | 735.54 Thousand USD | -268.259% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 98.421% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 79.159% |
| Skye Bioscience, Inc. | 4.61 Million USD | 41.31% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -205.012% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -1814.034% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 53.864% |
| IMV Inc. | 28.88 Million USD | 90.622% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -10431.914% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -19.94% |
| GB Sciences, Inc. | 1.75 Million USD | -53.964% |
| Alpha Cognition Inc. | 1.22 Million USD | -121.957% |
| HST Global, Inc. | 98.31 Thousand USD | -2655.015% |
| CSL Limited | 12.18 Billion USD | 99.978% |
| Halberd Corporation | 150 Thousand USD | -1705.802% |
| Enzolytics Inc. | 996.33 Thousand USD | -171.866% |
| Resverlogix Corp. | 6.49 Million USD | 58.27% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -467.268% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -959.776% |
| argenx SE | 20 Million USD | 86.456% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 94.055% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -26390.983% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.352% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1250.193% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -12.97% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1081.339% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 95.996% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 10.491% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -653.024% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 86.675% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -1722.153% |
| BioStem Technologies, Inc. | 4.71 Million USD | 42.508% |
| ONE Bio Corp. | 19.71 Million USD | 86.261% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -982.693% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -989.057% |
| Agentix Corp. | 50 Thousand USD | -5317.406% |
| LadRx Corporation | 33.6 Thousand USD | -7960.177% |
| Cell Source, Inc. | 9.25 Million USD | 70.73% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -258.197% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -258.197% |
| NovAccess Global Inc. | 2.19 Million USD | -23.13% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 61.703% |
| Itoco Inc. | 228.37 Thousand USD | -1086.066% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1183.898% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 45.641% |
| Kadimastem Ltd | 891.22 Thousand USD | -203.93% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -574.06% |
| CytoDyn Inc. | 30.07 Million USD | 90.994% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -459.321% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -669.853% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 65.362% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -2111.186% |
| Rebus Holdings, Inc. | 310 Thousand USD | -773.775% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 42.797% |
| International Stem Cell Corporation | 4.17 Million USD | 35.167% |
| Bioxytran, Inc. | 1.92 Million USD | -40.712% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -4239.966% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -24.201% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 67.428% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 68.448% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -74.139% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -910.71% |
| Neutra Corp. | 54.15 Thousand USD | -4901.667% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -48.017% |
| PureTech Health plc | 25.51 Million USD | 89.383% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -121.258% |
| IXICO plc | 472.02 Thousand USD | -473.85% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 82.526% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 95.65% |
| CSL Limited | 12.18 Billion USD | 99.978% |
| Cellectis S.A. | 92.77 Million USD | 97.08% |